CL2023003177A1 - Anticuerpos anti-clec12a y usos de los mismos solicitudes relacionadas - Google Patents

Anticuerpos anti-clec12a y usos de los mismos solicitudes relacionadas

Info

Publication number
CL2023003177A1
CL2023003177A1 CL2023003177A CL2023003177A CL2023003177A1 CL 2023003177 A1 CL2023003177 A1 CL 2023003177A1 CL 2023003177 A CL2023003177 A CL 2023003177A CL 2023003177 A CL2023003177 A CL 2023003177A CL 2023003177 A1 CL2023003177 A1 CL 2023003177A1
Authority
CL
Chile
Prior art keywords
antibodies
related applications
clec12a
fragments
fusion proteins
Prior art date
Application number
CL2023003177A
Other languages
English (en)
Spanish (es)
Inventor
Tomoki Yoshihara
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of CL2023003177A1 publication Critical patent/CL2023003177A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CL2023003177A 2021-04-26 2023-10-24 Anticuerpos anti-clec12a y usos de los mismos solicitudes relacionadas CL2023003177A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163179755P 2021-04-26 2021-04-26

Publications (1)

Publication Number Publication Date
CL2023003177A1 true CL2023003177A1 (es) 2024-05-24

Family

ID=81648460

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2023003177A CL2023003177A1 (es) 2021-04-26 2023-10-24 Anticuerpos anti-clec12a y usos de los mismos solicitudes relacionadas
CL2025002212A CL2025002212A1 (es) 2021-04-26 2025-07-24 Anticuerpos anti-clec12a y usos de los mismos

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2025002212A CL2025002212A1 (es) 2021-04-26 2025-07-24 Anticuerpos anti-clec12a y usos de los mismos

Country Status (18)

Country Link
US (1) US12600784B2 (https=)
EP (1) EP4330284A2 (https=)
JP (1) JP2024516645A (https=)
KR (1) KR20240004286A (https=)
CN (1) CN117545774A (https=)
AR (1) AR125451A1 (https=)
AU (1) AU2022266584A1 (https=)
BR (1) BR112023020365A2 (https=)
CA (1) CA3216770A1 (https=)
CL (2) CL2023003177A1 (https=)
CO (1) CO2023014316A2 (https=)
EC (1) ECSP23088759A (https=)
IL (1) IL307939A (https=)
MX (1) MX2023011710A (https=)
PE (1) PE20241789A1 (https=)
PH (1) PH12023552669A1 (https=)
TW (1) TW202309084A (https=)
WO (1) WO2022232044A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023011712A (es) 2021-04-26 2023-10-12 Millennium Pharm Inc Anticuerpos anti receptor de adhesion acoplado a proteinas g e2 (adgre2) y usos de los mismos.
CA3212596A1 (en) 2021-04-26 2022-11-03 Michel Sadelain Chimeric receptors targeting adgre2 and/or clec12a and uses thereof
WO2024254778A1 (en) * 2023-06-14 2024-12-19 Zhejiang Shimai Pharmaceutical Co., Ltd. Antibodies against cll1 and uses thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
IL79289A (en) 1985-07-05 1992-01-15 Whitehead Biomedical Inst Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus
ATE117375T1 (de) 1987-09-11 1995-02-15 Whitehead Biomedical Inst Transduktionsveränderte fibroblasten und ihre anwendung.
JP2914692B2 (ja) 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 内皮細胞の遺伝子修飾
WO1989007136A2 (en) 1988-02-05 1989-08-10 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ES2096750T3 (es) 1990-10-31 1997-03-16 Somatix Therapy Corp Vectores retroviricos utiles para la terapia genica.
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US6146361A (en) 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
WO1998047531A2 (en) 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
US6277099B1 (en) 1999-08-06 2001-08-21 Becton, Dickinson And Company Medication delivery pen
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
DE60135352D1 (de) 2000-08-30 2008-09-25 Univ Johns Hopkins Vorrichtung zur intraokularen wirkstoffverabreichung
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
WO2003022330A2 (en) 2001-09-12 2003-03-20 Becton, Dickinson And Company Microneedle-based pen device for drug delivery and method for using same
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US20040102469A1 (en) 2002-09-13 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for reducing the mortality rate
GB0222023D0 (en) 2002-09-21 2002-10-30 Aventis Pharma Ltd Inhaler
FR2849436B1 (fr) 2002-12-27 2007-01-05 Patrick Frayssinet Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro
US20060167435A1 (en) 2003-02-18 2006-07-27 Adamis Anthony P Transscleral drug delivery device and related methods
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
JP2010533181A (ja) 2007-07-13 2010-10-21 アボツト・バイオテクノロジー・リミテツド ＴＮＦα阻害剤の肺投与のための方法及び組成物
JP5932670B2 (ja) 2010-03-11 2016-06-08 ライナット ニューロサイエンス コーポレイション ｐＨ依存性の抗原結合を有する抗体
EP2622074B1 (en) 2010-09-30 2014-11-12 Board Of Trustees Of Northern Illinois University Library-based methods and compositions for introducing molecular switch functionality into protein affinity reagents
US9163090B2 (en) * 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
HUE042040T2 (hu) 2012-09-27 2019-06-28 Merus Nv Bispecifikus IGG antitestek mint T-sejt kapcsolók
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
MA40579A (fr) 2014-09-12 2016-03-17 Genentech Inc Anticorps anti-cll-1 et immunoconjugués
US10501545B2 (en) * 2015-06-16 2019-12-10 Genentech, Inc. Anti-CLL-1 antibodies and methods of use
EA202090718A1 (ru) 2017-09-14 2020-07-01 Драгонфлай Терапьютикс, Инк. Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1)
WO2019108065A1 (en) * 2017-12-01 2019-06-06 Merus N.V. Use of bispecific antibody and il-15 for combination therapy
MX2020007338A (es) * 2018-01-09 2020-11-06 H Lee Moffitt Cancer Ct & Res Composiciones y métodos para el direccionamiento a tipos de cáncer que expresan clec12a.
SG11202106765XA (en) * 2018-12-27 2021-07-29 Gigagen Inc Anti-pd-1 binding proteins and methods of use thereof
BR112021020999A2 (pt) * 2019-05-04 2021-12-14 Inhibrx Inc Polipeptídeos de ligação à clec12a e usos dos mesmos
JP7512394B2 (ja) 2020-05-06 2024-07-08 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質
CA3212596A1 (en) 2021-04-26 2022-11-03 Michel Sadelain Chimeric receptors targeting adgre2 and/or clec12a and uses thereof
MX2023011712A (es) 2021-04-26 2023-10-12 Millennium Pharm Inc Anticuerpos anti receptor de adhesion acoplado a proteinas g e2 (adgre2) y usos de los mismos.

Also Published As

Publication number Publication date
US20230111279A1 (en) 2023-04-13
WO2022232044A2 (en) 2022-11-03
ECSP23088759A (es) 2024-01-31
US12600784B2 (en) 2026-04-14
AU2022266584A1 (en) 2023-10-12
PH12023552669A1 (en) 2024-02-19
CL2025002212A1 (es) 2025-10-24
CA3216770A1 (en) 2022-11-03
IL307939A (en) 2023-12-01
WO2022232044A3 (en) 2022-12-08
AR125451A1 (es) 2023-07-19
TW202309084A (zh) 2023-03-01
AU2022266584A9 (en) 2023-10-26
EP4330284A2 (en) 2024-03-06
BR112023020365A2 (pt) 2023-11-21
JP2024516645A (ja) 2024-04-16
CO2023014316A2 (es) 2023-11-20
KR20240004286A (ko) 2024-01-11
MX2023011710A (es) 2023-10-12
CN117545774A (zh) 2024-02-09
PE20241789A1 (es) 2024-09-06

Similar Documents

Publication Publication Date Title
ECSP23088752A (es) Anticuerpos anti-adgre2 y usos de los mismos
CL2023003177A1 (es) Anticuerpos anti-clec12a y usos de los mismos solicitudes relacionadas
DOP2017000047A (es) Anticuerpos anti-lag3 y fragmentos de unión a antígeno
CL2019003520A1 (es) Anticuerpos que se unen específicamente a pd-1 y procedimientos de uso.
CL2024003715A1 (es) Proteína de unión multiespecífica que se une a nkg2d, cd33 y cd16; composición; y uso.
ECSP20082991A (es) Agentes aglutinantes del psma y usos de estos
UY37591A (es) Conjugados de fármaco anticuerpo
MX2019014465A (es) Anticuerpos especificos para flt3 y sus usos.
CO2020014506A2 (es) Anticuerpos anti-cd3 y usos de estos
MX2020000342A (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos.
CO2020014345A2 (es) Anticuerpos específicos para gucy2c y sus usos
AR116718A1 (es) Proteínas de unión triespecíficas anti-cd38, anti-cd28 y anti-cd3 y métodos de uso para tratar infección vírica
PE20211860A1 (es) Proteinas de union multiespecificas que se unen a bcma, nkg2d y cd16 y metodos de uso
UY37698A (es) Proteínas de unión a antígenos trem2 y usos de estas
MX2021007768A (es) Anticuerpos anti-ctla4 y metodos de uso de los mismos.
MX2016012094A (es) Composiciones de anticuerpos para tratamiento tumoral.
CL2018000908A1 (es) Anticuerpos anti-lag3 y su uso para tratar cáncer o infección viral.
MX2019011961A (es) Terapias combinadas dirigidas a proteina 1 de muerte celular programada (pd-1), proteina 3 de dominio de mucina y dominio inmunoglobulina de los linfocitos t (tim-3), y gen de activacion de linfocitos 3 (lag-3).
AR106570A1 (es) Anticuerpos anti-psma, moléculas de unión al antígeno biespecíficas que se unen a psma y cd3, y usos de estos
CO2022009737A2 (es) Anticuerpos anti-ly6g6d y métodos de uso
MX2020013428A (es) Anticuerpos monoclonales contra inmunoglobulina de celulas t y molecula que contiene dominio de mucina-3 (tim-3) humana.
BR112022011824A2 (pt) Anticorpos de cadeia pesada que se ligam a cd38
EA202092302A1 (ru) Антитела к trem-1 и их применения
CO2023002375A2 (es) Anticuerpos contra ilt2 y uso de los mismos
MX2021003119A (es) Anticuerpos anti-klrg1.